One single-arm prospective clinical study (26) explored the efficacy and safety of ASCT bridging CD19/CD22 CAR-T therapy in 42 R/R aggressive B-cell non-Hodgkin lymphoma (B-NHL) patients, at a median follow-up of 24.3 months, the OR rate was 90.5%, the 2-year PFS rate was 83.3%, and the median PFS and OS were not reached. This evidence concerns the gene CD22 and B-cell non-Hodgkin lymphoma.